Medroxalol

Last updated
Medroxalol
Medroxalol.svg
Identifiers
  • 5-(2-{[4-(1,3-Benzodioxol-5-yl)-2-butanyl]amino}-1-hydroxyethyl)-2-hydroxybenzamide
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
ECHA InfoCard 100.054.618 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C20H24N2O5
Molar mass 372.421 g·mol−1
3D model (JSmol)
  • O=C(N)c1cc(ccc1O)C(O)CNC(C)CCc2ccc3OCOc3c2
  • InChI=1S/C20H24N2O5/c1-12(2-3-13-4-7-18-19(8-13)27-11-26-18)22-10-17(24)14-5-6-16(23)15(9-14)20(21)25/h4-9,12,17,22-24H,2-3,10-11H2,1H3,(H2,21,25)
  • Key:MPQWSYJGFLADEW-UHFFFAOYSA-N

Medroxalol is a vasodilator beta blocker also classified as a mixed receptor blocker as it blocks both alpha and beta receptors. [1]

Contents

Synthesis

Medroxalol synthesis: Medroxalol synthesis.svg
Medroxalol synthesis:

For the first step, salicylamide (1) is the subject of a Friedel-Crafts acetylation and then the aromatic methyl ketone is halogenated. in the usual manner. The bromide in 2 is then displaced by the nitrogen in N-benzyl-1-(3',4'-methylenedioxyphenyl)-3-butylamine (3), which is itself prepared by reductive amination on the corresponding ketone. The product of the last step (4) is catalytically hydrogenated. This serves the dual purpose both of reducing the ketone and removing the benzyl protecting group affording the product medroxalol (5). Note that a benzyl protecting group is not necessarily used.

See also

References

  1. ↑ Dage RC, Cheng HC, Woodward JK (1981). "Cardiovascular properties of medroxalol, a new antihypertensive drug". Journal of Cardiovascular Pharmacology. 3 (2): 299–315. doi: 10.1097/00005344-198103000-00009 . PMID   6166802.
  2. ↑ J. T. Suh and T. M. Bare, U.S. patent 3,883,560 ; Chem.Abstr. 83, 78914J (1975).


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.